Skip to main content
Hikal Ltd. logo

Hikal Ltd. — Investor Relations & Filings

Ticker · HIKAL ISIN · INE475B01022 LEI · 335800OLTGHHYZWTF859 BSE.NS Manufacturing
Filings indexed 715 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country IN India
Listing BSE.NS HIKAL

About Hikal Ltd.

https://www.hikal.com

Hikal Ltd. provides solutions across the life sciences value chain, specializing in the development and manufacturing of active ingredients, intermediates, and formulations. The company operates through two primary business segments: Pharmaceuticals and Crop Protection. In the pharmaceutical division, it focuses on the production of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for various therapeutic areas. The crop protection segment involves the contract manufacturing of pesticides, herbicides, and fungicides for global agrochemical leaders. Hikal offers comprehensive Contract Research and Manufacturing Services (CRAMS), leveraging its research and development capabilities to support clients from early-stage development to commercial-scale production. Its facilities adhere to international quality standards, maintaining a strong track record of regulatory compliance with global health authorities.

Recent filings

Filing Released Lang Actions
Intimation of Q4 & FY 2026 Earnings Call.
Regulatory Filings Classification · 85% confidence The document is an announcement to stock exchanges under SEBI Listing Regulations informing investors of an upcoming earnings conference call for Q4 & FY26. It contains no financial data or results, nor a conference call transcript or presentation materials—just logistical details. It is a general regulatory announcement/fallback filing under Reg.30, so it falls under Regulatory Filings (RNS).
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI Listing Regulations providing notice of an earnings conference call (date, time, dial-in details) but contains no financial data, results or transcript. It is not the earnings release itself nor a full report or transcript. It is a regulatory disclosure/announcement, so it falls under the general Regulatory Filings category (RNS).
2026-05-20 English
Hikal Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Audited Financial Results (Standalone ....
Regulatory Filings Classification · 85% confidence The document is a formal notice to stock exchanges under SEBI Listing Regulations (Regulation 29) announcing a Board Meeting date. It does not present financial results or actual data, nor does it announce management changes. It is a compliance/regulatory announcement falling under general regulatory filings.
2026-05-20 English
Retirement
Regulatory Filings
2026-04-14 English
Reply to Clarification- Financial results
Regulatory Filings
2026-04-13 English
Copy of Newspaper Publication
Regulatory Filings
2026-04-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.